Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003599600 | SCV004505497 | uncertain significance | Neurofibromatosis, type 1 | 2023-03-02 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. This variant has not been reported in the literature in individuals affected with NF1-related conditions. This variant is not present in population databases (gnomAD no frequency). This variant, c.4564_4566del, results in the deletion of 1 amino acid(s) of the NF1 protein (p.Leu1522del), but otherwise preserves the integrity of the reading frame. |
Ambry Genetics | RCV004558194 | SCV005048213 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-05-25 | criteria provided, single submitter | clinical testing | The c.4564_4566delCTT variant (also known as p.L1522del) is located in coding exon 34 of the NF1 gene. This variant results from an in-frame CTT deletion at nucleotide positions 4564 to 4566. This results in the in-frame deletion of a leucine at codon 1522. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |